Publications by authors named "Clifford D Jones"

Claim this Profile
T
The Wnt Pathway Inhibitor RXC004 Blocks Tumor Growth and Reverses Immune Evasion in Wnt Ligand-dependent Cancer Models.
Caroline Phillips, Inder Bhamra, Catherine Eagle, Eimear Flanagan, Richard Armer, Clifford D Jones

Cancer Res Commun· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in -Mutant Tumor Models when Combined with the MEK Inhibitor, Selumetinib.
Vikki Flemington, Emma J Davies, David Robinson, Linda C Sandin, Oona Delpuech, Clifford D Jones

Mol Cancer Ther· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a Potent and Selective Oral Inhibitor of ERK1/2 (AZD0364) That Is Efficacious in Both Monotherapy and Combination Therapy in Models of Nonsmall Cell Lung Cancer (NSCLC).
Richard A Ward, Mark J Anderton, Paul Bethel, Jason Breed, Calum Cook, Clifford D Jones, Christopher R Jones

J Med Chem· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cell-Active Small Molecule Inhibitors of the DNA-Damage Repair Enzyme Poly(ADP-ribose) Glycohydrolase (PARG): Discovery and Optimization of Orally Bioavailable Quinazolinedione Sulfonamides.
Bohdan Waszkowycz, Kate M Smith, Alison E McGonagle, Allan M Jordan, Ben Acton, Clifford D Jones, Stuart Jones

J Med Chem· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-Guided Discovery of Potent and Selective Inhibitors of ERK1/2 from a Modestly Active and Promiscuous Chemical Start Point.
Richard A Ward, Paul Bethel, Calum Cook, Emma Davies, Judit E Debreczeni, Clifford D Jones, Christopher R Jones

J Med Chem· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cellularly active N-hydroxyurea FEN1 inhibitors block substrate entry to the active site.
Jack C Exell, Mark J Thompson, L David Finger, Steven J Shaw, Judit Debreczeni, Clifford D Jones

Nat Chem Biol· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a Potent, Selective, Orally Bioavailable, and Efficacious Novel 2-(Pyrazol-4-ylamino)-pyrimidine Inhibitor of the Insulin-like Growth Factor-1 Receptor (IGF-1R).
Sébastien L Degorce, Scott Boyd, Jon O Curwen, Richard Ducray, Christopher T Halsall, Clifford D Jones

J Med Chem· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-Guided Design of Highly Selective and Potent Covalent Inhibitors of ERK1/2.
Richard A Ward, Nicola Colclough, Mairi Challinor, Judit E Debreczeni, Kay Eckersley, Clifford D Jones, Christopher R Jones

J Med Chem· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel and versatile synthesis of disubstituted 1,2-dihydro-1,2,4-triazol-3-ones.
Mark A Graham, Paul A Bethel, Jonathan Burgess, Gary Fairley, Steve C Glossop, Clifford D Jones

Org Lett· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel imidazo[1,2-a]pyridine based inhibitors of the IGF-1 receptor tyrosine kinase: optimization of the aniline.
Richard Ducray, Clifford D Jones, Frederic H Jung, Iain Simpson, Jon Curwen

Bioorg Med Chem Lett· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sustained Mps1 activity is required in mitosis to recruit O-Mad2 to the Mad1-C-Mad2 core complex.
Laura Hewitt, Anthony Tighe, Stefano Santaguida, Anne M White, Clifford D Jones

J Cell Biol· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Imidazole pyrimidine amides as potent, orally bioavailable cyclin-dependent kinase inhibitors.
Clifford D Jones, David M Andrews, Andrew J Barker, Kevin Blades, Kate F Byth

Bioorg Med Chem Lett· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The discovery of AZD5597, a potent imidazole pyrimidine amide CDK inhibitor suitable for intravenous dosing.
Clifford D Jones, David M Andrews, Andrew J Barker, Kevin Blades, Paula Daunt

Bioorg Med Chem Lett· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Unusual reactivity of N-acyl imides: N-aroyl-1,2,4-dithiazolidine-3,5-diones as acyl isocyanate equivalents.
Mark E Wood, Victoria M Annis, Clifford D Jones

Org Biomol Chem· November 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design of a potent, soluble glucokinase activator with excellent in vivo efficacy.
Darren McKerrecher, Joanne V Allen, Peter W R Caulkett, Craig S Donald, Mark L Fenwick, Clifford D Jones

Bioorg Med Chem Lett· May 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery, synthesis and biological evaluation of novel glucokinase activators.
Darren McKerrecher, Joanne V Allen, Suzanne S Bowker, Scott Boyd, Peter W R Caulkett, Clifford D Jones

Bioorg Med Chem Lett· April 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis